US7671200B2
(en)
|
1999-10-27 |
2010-03-02 |
Cytokinetics, Inc. |
Quinazolinone KSP inhibitors
|
US7230000B1
(en)
*
|
1999-10-27 |
2007-06-12 |
Cytokinetics, Incorporated |
Methods and compositions utilizing quinazolinones
|
US6545004B1
(en)
|
1999-10-27 |
2003-04-08 |
Cytokinetics, Inc. |
Methods and compositions utilizing quinazolinones
|
US6667300B2
(en)
*
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
US6608053B2
(en)
|
2000-04-27 |
2003-08-19 |
Yamanouchi Pharmaceutical Co., Ltd. |
Fused heteroaryl derivatives
|
US6403588B1
(en)
|
2000-04-27 |
2002-06-11 |
Yamanouchi Pharmaceutical Co., Ltd. |
Imidazopyridine derivatives
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
IL149462A0
(en)
*
|
2001-05-09 |
2002-11-10 |
Warner Lambert Co |
Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
|
US6689782B2
(en)
*
|
2001-07-16 |
2004-02-10 |
Essential Therapeutics, Inc. |
Fungal efflux pump inhibitors
|
AU2002329000A1
(en)
*
|
2001-09-24 |
2003-04-07 |
University Of Aarhus |
Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1
|
US20060067938A1
(en)
*
|
2001-10-26 |
2006-03-30 |
Sherif Daouti |
Methods for the treatment of osteoarthritis and compositions thereof
|
US7060705B2
(en)
|
2001-11-07 |
2006-06-13 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
AU2003213092A1
(en)
*
|
2002-02-15 |
2003-09-09 |
Smithkline Beecham Corporation |
Syntheses of quinazolinones
|
PE20030968A1
(es)
|
2002-02-28 |
2004-01-12 |
Novartis Ag |
Derivados de 5-feniltiazol como inhibidores de cinasas
|
US7381730B2
(en)
*
|
2002-03-15 |
2008-06-03 |
Bristol-Myers Squibb Company |
3-arylquinazoline derivatives as selective estrogen receptor beta modulators
|
WO2003084544A2
(en)
*
|
2002-04-04 |
2003-10-16 |
Cv Therapeutics, Inc. |
Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
|
CA2485148A1
(en)
*
|
2002-05-09 |
2003-11-20 |
Cytokinetics, Inc. |
Pyrimidinone compounds, compositions and methods
|
WO2003097053A1
(en)
*
|
2002-05-09 |
2003-11-27 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
WO2003103575A2
(en)
*
|
2002-05-23 |
2003-12-18 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
EP1556357A4
(en)
*
|
2002-06-14 |
2006-09-13 |
Cytokinetics Inc |
COMPOUNDS, COMPOSITIONS AND METHODS
|
AU2003248927A1
(en)
*
|
2002-07-10 |
2004-01-23 |
Massachusetts Institute Of Technology |
Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
|
US7211580B2
(en)
*
|
2002-07-23 |
2007-05-01 |
Cytokinetics, Incorporated |
Compounds, compositions, and methods
|
AU2003262747A1
(en)
*
|
2002-08-21 |
2004-03-11 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
US7557115B2
(en)
*
|
2002-09-30 |
2009-07-07 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
JP4790266B2
(ja)
|
2002-09-30 |
2011-10-12 |
バイエル・シエリング・フアーマ・アクチエンゲゼルシヤフト |
縮合アゾールピリミジン誘導体
|
EP1553947A4
(en)
*
|
2002-10-21 |
2006-11-29 |
Bristol Myers Squibb Co |
QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
|
AU2003280188A1
(en)
|
2002-12-06 |
2004-06-30 |
Warner-Lambert Company Llc |
Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
|
BR0317572A
(pt)
*
|
2002-12-20 |
2005-11-22 |
Warner Lambert Co |
Benzoxazinas e seus derivados como inibidores de pi3ks
|
US20040242568A1
(en)
|
2003-03-25 |
2004-12-02 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
AU2004262533A1
(en)
|
2003-08-08 |
2005-02-17 |
Ulysses Pharmaceutical Products Inc. |
Halogenated quinazolinyl nitrofurans as antibacterial agents
|
US7790736B2
(en)
|
2003-08-13 |
2010-09-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
WO2005016349A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Icos Corporation |
Methods of inhibiting leukocyte accumulation
|
US20050043239A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Jason Douangpanya |
Methods of inhibiting immune responses stimulated by an endogenous factor
|
US7790734B2
(en)
*
|
2003-09-08 |
2010-09-07 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
JP2007513058A
(ja)
*
|
2003-09-08 |
2007-05-24 |
武田薬品工業株式会社 |
ジペプチジルぺプチダーゼ阻害剤
|
BRPI0414533A
(pt)
|
2003-09-18 |
2006-11-07 |
Conforma Therapeutics Corp |
composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
|
EP1682534A2
(en)
*
|
2003-11-03 |
2006-07-26 |
Cytokinetics, Inc. |
Pyrimidin-4-one compounds, compositions, and methods
|
CA2552664A1
(en)
*
|
2004-01-08 |
2005-07-28 |
Michigan State University |
Methods for treating and preventing hypertension and hypertension-related disorders
|
CA2555824C
(en)
*
|
2004-02-13 |
2011-06-07 |
Banyu Pharmaceutical Co., Ltd. |
Fused-ring 4-oxopyrimidine derivative
|
JP4866723B2
(ja)
*
|
2004-02-26 |
2012-02-01 |
協和発酵キリン株式会社 |
好中球性炎症疾患の予防及び/または治療剤
|
CN102134229B
(zh)
*
|
2004-03-15 |
2020-08-04 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
CA2563038C
(en)
|
2004-04-02 |
2013-10-29 |
Gaik Beng Kok |
Neurologically-active compounds
|
EP1755588A1
(en)
*
|
2004-05-06 |
2007-02-28 |
Cancer Research Technology Limited |
Compounds and compositions for treatment of cancer
|
CA2566436C
(en)
*
|
2004-05-13 |
2011-05-10 |
Vanderbilt University |
Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
|
ES2605792T3
(es)
|
2004-05-13 |
2017-03-16 |
Icos Corporation |
Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
|
CA2567883A1
(en)
*
|
2004-05-25 |
2005-12-15 |
Icos Corporation |
Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
|
CA2569406A1
(en)
*
|
2004-06-04 |
2005-12-22 |
Icos Corporation |
Methods for treating mast cell disorders
|
EP1800693B1
(en)
*
|
2004-08-24 |
2013-07-17 |
Chugai Seiyaku Kabushiki Kaisha |
Adjuvant therapy with the use of anti-glypican 3 antibody
|
US20060079573A1
(en)
*
|
2004-10-10 |
2006-04-13 |
Jakob Vinten-Johansen |
Methods and compositions for preventing vasospasm
|
EP1831225A2
(en)
|
2004-11-19 |
2007-09-12 |
The Regents of the University of California |
Anti-inflammatory pyrazolopyrimidines
|
WO2006068978A2
(en)
|
2004-12-21 |
2006-06-29 |
Takeda Pharmaceutial Company Limited |
Dipeptidyl peptidase inhibitors
|
CA2598409A1
(en)
*
|
2005-02-17 |
2006-08-24 |
Icos Corporation |
Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
|
US20090131664A1
(en)
*
|
2005-07-05 |
2009-05-21 |
Atsushi Akao |
Method for Producing 4(3H)-Quinazolinone Derivative
|
UA97469C2
(uk)
*
|
2005-07-25 |
2012-02-27 |
Емерджент Продакт Дівелопмент Сіетл, Елелсі |
Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
|
EP1917252B1
(en)
*
|
2005-08-26 |
2014-01-01 |
Merck Serono SA |
Pyrazine derivatives and use as pi3k inhibitors
|
PL1942898T5
(pl)
|
2005-09-14 |
2014-10-31 |
Takeda Pharmaceuticals Co |
Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
|
US20070060529A1
(en)
*
|
2005-09-14 |
2007-03-15 |
Christopher Ronald J |
Administration of dipeptidyl peptidase inhibitors
|
CN102675221A
(zh)
*
|
2005-09-16 |
2012-09-19 |
武田药品工业株式会社 |
用于制备嘧啶二酮衍生物的方法中的中间体
|
US20070087005A1
(en)
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
US8217042B2
(en)
|
2005-11-11 |
2012-07-10 |
Zentaris Gmbh |
Pyridopyrazines and their use as modulators of kinases
|
CA2628039A1
(en)
|
2005-11-11 |
2007-05-18 |
Aeterna Zentaris Gmbh |
Novel pyridopyrazines and their use as modulators of kinases
|
EP1790342A1
(de)
|
2005-11-11 |
2007-05-30 |
Zentaris GmbH |
Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
|
PT3184526T
(pt)
|
2005-12-13 |
2018-12-19 |
Incyte Holdings Corp |
Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus
|
WO2007112368A1
(en)
*
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Preparation of (r)-3-aminopiperidine dihydrochloride
|
EA200870409A1
(ru)
*
|
2006-04-04 |
2009-04-28 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Антагонисты киназы pi3
|
GB0610242D0
(en)
*
|
2006-05-23 |
2006-07-05 |
Novartis Ag |
Organic compounds
|
NZ573646A
(en)
*
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
KR101419075B1
(ko)
*
|
2006-08-08 |
2014-07-11 |
아스카 세이야쿠 가부시키가이샤 |
퀴나졸린 유도체
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
GEP20125701B
(en)
*
|
2006-09-13 |
2012-12-10 |
Takeda Pharmaceuticals Co |
Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
|
WO2008041118A2
(en)
*
|
2006-10-04 |
2008-04-10 |
Pfizer Products Inc. |
Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
|
CN101522682A
(zh)
|
2006-10-30 |
2009-09-02 |
诺瓦提斯公司 |
作为抗炎剂的杂环化合物
|
JP5313909B2
(ja)
*
|
2006-11-13 |
2013-10-09 |
アイコス コーポレイション |
炎症性疾患および癌の処置のためのチエノピリミジノン
|
TW200838536A
(en)
*
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
US20080312259A1
(en)
|
2007-06-13 |
2008-12-18 |
Incyte Corporation |
SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
|
UY31137A1
(es)
*
|
2007-06-14 |
2009-01-05 |
Smithkline Beecham Corp |
Derivados de quinazolina como inhibidores de la pi3 quinasa
|
WO2009046448A1
(en)
*
|
2007-10-04 |
2009-04-09 |
Intellikine, Inc. |
Chemical entities and therapeutic uses thereof
|
US20090131512A1
(en)
*
|
2007-10-31 |
2009-05-21 |
Dynavax Technologies Corp. |
Inhibition of type I in IFN production
|
GEP20125635B
(en)
*
|
2007-11-13 |
2012-09-10 |
Icos Corp |
Inhibitors of human phosphatidyl-inositol 3-kinase delta
|
RU2537549C2
(ru)
*
|
2008-01-04 |
2015-01-10 |
Интелликайн ЭлЭлСи |
Некоторые химические структуры, композиции и способы
|
MX2010007418A
(es)
*
|
2008-01-04 |
2010-11-12 |
Intellikine Inc |
Ciertas entidades quimicas, composiciones y metodos.
|
US8193182B2
(en)
*
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
NZ603059A
(en)
*
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
US10517839B2
(en)
*
|
2008-06-09 |
2019-12-31 |
Cornell University |
Mast cell inhibition in diseases of the retina and vitreous
|
US20110224223A1
(en)
*
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
BRPI0915231A2
(pt)
|
2008-07-08 |
2018-06-12 |
Intellikine Inc |
compostos inibidores de quinase e métodos de uso
|
WO2010036380A1
(en)
|
2008-09-26 |
2010-04-01 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
DK2358720T3
(en)
|
2008-10-16 |
2016-06-06 |
Univ California |
Heteroarylkinaseinhibitorer fused-ring
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
KR20110083730A
(ko)
*
|
2008-11-13 |
2011-07-20 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
Cd37 면역치료제 병용 요법 및 이의 용도
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
WO2010057048A1
(en)
|
2008-11-13 |
2010-05-20 |
Calistoga Pharmaceuticals Inc. |
Therapies for hematologic malignancies
|
EP2365810A2
(en)
*
|
2008-12-04 |
2011-09-21 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
|
CA2755935A1
(en)
|
2009-02-12 |
2010-08-19 |
Astellas Pharma Inc. |
Hetero ring derivative
|
CN102439012A
(zh)
|
2009-03-24 |
2012-05-02 |
吉里德卡利斯托加公司 |
2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
AR075974A1
(es)
|
2009-03-27 |
2011-05-11 |
Pathway Therapeutics Ltd |
Pirimidinil y 1,3,5-triazinilbencimidazolsulfonamidas y su uso en terapia del cancer
|
KR20120005523A
(ko)
*
|
2009-04-20 |
2012-01-16 |
길리아드 칼리스토가 엘엘씨 |
고형 종양의 치료 방법
|
CA2760791C
(en)
|
2009-05-07 |
2017-06-20 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
JP2012531435A
(ja)
*
|
2009-06-25 |
2012-12-10 |
アムジエン・インコーポレーテツド |
PI3K阻害剤としての4H−ピリド[1,2−a]ピリミジン−4−オン誘導体
|
EP2451802A1
(en)
|
2009-07-07 |
2012-05-16 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
AU2010276160A1
(en)
*
|
2009-07-21 |
2012-02-09 |
Gilead Calistoga Llc |
Treatment of liver disorders with PI3K inhibitors
|
GEP201706639B
(en)
|
2009-08-17 |
2017-03-27 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
GB0918249D0
(en)
|
2009-10-19 |
2009-12-02 |
Respivert Ltd |
Compounds
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
KR102012398B1
(ko)
|
2009-11-05 |
2019-08-20 |
리젠 파마슈티컬스 소시에떼 아노님 |
신규한 벤조피란 키나제 조절제
|
TWI766281B
(zh)
|
2010-03-10 |
2022-06-01 |
美商英塞特控股公司 |
作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
|
EP2571357B1
(en)
|
2010-05-21 |
2016-07-06 |
Infinity Pharmaceuticals, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
PE20130216A1
(es)
|
2010-05-21 |
2013-02-27 |
Incyte Corp |
Formulacion topica para un inhibidor de jak
|
WO2011159726A2
(en)
|
2010-06-14 |
2011-12-22 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
WO2012020762A1
(ja)
|
2010-08-10 |
2012-02-16 |
アステラス製薬株式会社 |
へテロ環化合物
|
PL2611300T3
(pl)
|
2010-09-03 |
2016-10-31 |
|
Podstawione skondensowane pochodne dihydropirymidynonów
|
WO2012040634A1
(en)
|
2010-09-24 |
2012-03-29 |
Gilead Calistoga Llc |
Atropisomers of pi3k-inhibiting compounds
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
UY33337A
(es)
|
2010-10-18 |
2011-10-31 |
Respivert Ltd |
DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AR083933A1
(es)
|
2010-11-19 |
2013-04-10 |
Incyte Corp |
Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
|
AR084824A1
(es)
|
2011-01-10 |
2013-06-26 |
Intellikine Inc |
Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
|
AR085397A1
(es)
|
2011-02-23 |
2013-09-25 |
Intellikine Inc |
Combinacion de inhibidores de quinasa y sus usos
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
WO2012121953A1
(en)
|
2011-03-08 |
2012-09-13 |
The Trustees Of Columbia University In The City Of New York |
Methods and pharmaceutical compositions for treating lymphoid malignancy
|
EP2691384B1
(en)
|
2011-03-28 |
2016-10-26 |
MEI Pharma, Inc. |
(alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
|
CN102731525A
(zh)
*
|
2011-04-08 |
2012-10-17 |
上海艾力斯医药科技有限公司 |
苯并吗啉衍生物
|
EP2518070A1
(en)
|
2011-04-29 |
2012-10-31 |
Almirall, S.A. |
Pyrrolotriazinone derivatives as PI3K inhibitors
|
CN107337659A
(zh)
|
2011-05-04 |
2017-11-10 |
理森制药股份公司 |
作为蛋白激酶调节剂的新颖化合物
|
EA201490042A1
(ru)
|
2011-06-20 |
2014-10-30 |
Инсайт Корпорейшн |
Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
|
CN103946226A
(zh)
|
2011-07-19 |
2014-07-23 |
无限药品股份有限公司 |
杂环化合物及其应用
|
AU2012284088B2
(en)
|
2011-07-19 |
2015-10-08 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
WO2013032591A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
AU2012341028C1
(en)
|
2011-09-02 |
2017-10-19 |
Mount Sinai School Of Medicine |
Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
|
ES2848273T3
(es)
|
2012-03-05 |
2021-08-06 |
Gilead Calistoga Llc |
Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
SI2870157T1
(en)
|
2012-07-04 |
2018-02-28 |
Rhizen Pharmaceuticals S.A. |
SELECTIVE PI3K-DELTA INHIBITORS
|
UY34893A
(es)
|
2012-07-10 |
2014-02-28 |
Takeda Pharmaceutical |
Derivados de azaindol
|
WO2014023083A1
(zh)
*
|
2012-08-08 |
2014-02-13 |
山东亨利医药科技有限责任公司 |
PI3Kδ抑制剂
|
WO2014052669A1
(en)
|
2012-09-26 |
2014-04-03 |
The Regents Of The University Of California |
Modulation of ire1
|
PE20150637A1
(es)
*
|
2012-10-16 |
2015-05-08 |
Almirall Sa |
Derivados de pirrolotriazinona como inhibidores de pi3k
|
KR20150079745A
(ko)
|
2012-11-08 |
2015-07-08 |
리젠 파마슈티컬스 소시에떼 아노님 |
Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
|
SG11201503695XA
(en)
|
2012-11-15 |
2015-06-29 |
Incyte Corp |
Sustained-release dosage forms of ruxolitinib
|
JP6297582B2
(ja)
*
|
2012-11-16 |
2018-03-20 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
ヒトホスファチジルイノシトール3−キナーゼデルタのプリン阻害剤
|
AU2013364070B2
(en)
|
2012-12-21 |
2016-10-27 |
Gilead Calistoga Llc |
Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
|
TW201441216A
(zh)
|
2012-12-21 |
2014-11-01 |
Gilead Calistoga Llc |
肌醇磷酯3-激酶的抑制劑
|
HUE057262T2
(hu)
|
2013-03-06 |
2022-04-28 |
Incyte Holdings Corp |
Eljárás és köztitermékek JAK inhibitor elõállítására
|
JO3279B1
(ar)
|
2013-03-15 |
2018-09-16 |
Respivert Ltd |
مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
US9227977B2
(en)
|
2013-03-15 |
2016-01-05 |
Respivert Ltd. |
Phosphoinositide 3-kinase inhibitors
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
MX347988B
(es)
|
2013-06-14 |
2017-05-19 |
Gilead Sciences Inc |
Inhibidores de fosfatidilinositol 3-cinasa.
|
EP3016955B1
(en)
|
2013-07-02 |
2018-03-07 |
Rhizen Pharmaceuticals S.A. |
Pi3k protein kinase inhibitors, particularly delta and/or gamma inhibitors
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
US9655854B2
(en)
|
2013-08-07 |
2017-05-23 |
Incyte Corporation |
Sustained release dosage forms for a JAK1 inhibitor
|
SG11201600028YA
(en)
|
2013-09-22 |
2016-02-26 |
Calitor Sciences Llc |
Substituted aminopyrimidine compounds and methods of use
|
JP6466924B2
(ja)
|
2013-10-04 |
2019-02-06 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015054355A1
(en)
|
2013-10-10 |
2015-04-16 |
Acetylon Pharmaceuticals, Inc. |
Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
SG11201604825VA
(en)
|
2013-12-20 |
2016-07-28 |
Gilead Calistoga Llc |
Process methods for phosphatidylinositol 3-kinase inhibitors
|
AU2014364414A1
(en)
|
2013-12-20 |
2016-06-30 |
Gilead Calistoga Llc |
Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
|
UY35945A
(es)
|
2014-01-09 |
2015-08-31 |
Takeda Pharmaceutical |
Derivados de azaindol
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
US9775844B2
(en)
|
2014-03-19 |
2017-10-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
DK3149000T3
(da)
|
2014-05-27 |
2021-08-30 |
Rhizen Pharmaceuticals S A |
Krystallinsk tosylatsalt af en pi3k-delta-selektiv inhibitor til anvendelse i farmaceutiske formuleringer
|
ES2833025T3
(es)
*
|
2014-06-13 |
2021-06-14 |
Gilead Sciences Inc |
Inhibidores de fosfatidilinositol 3-quinasa
|
MX2016016528A
(es)
|
2014-06-13 |
2017-03-27 |
Gilead Sciences Inc |
Inhibidores de fosfatidilinositol 3-quinasa.
|
KR20170012560A
(ko)
|
2014-06-13 |
2017-02-02 |
길리애드 사이언시즈, 인코포레이티드 |
포스파티딜이노시톨 3-키나제 억제제
|
ES2750357T3
(es)
|
2014-06-13 |
2020-03-25 |
Gilead Sciences Inc |
Inhibidores de fosfatidilinositol 3-quinasa
|
NZ726055A
(en)
|
2014-06-13 |
2018-04-27 |
Gilead Sciences Inc |
Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
|
NZ727185A
(en)
|
2014-06-24 |
2018-04-27 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors
|
KR20170082490A
(ko)
|
2014-07-04 |
2017-07-14 |
루핀 리미티드 |
Pi3k 억제제로서 퀴놀리지논 유도체
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
WO2017003723A1
(en)
|
2015-07-01 |
2017-01-05 |
Crinetics Pharmaceuticals, Inc. |
Somatostatin modulators and uses thereof
|
EP3318879B1
(en)
|
2015-07-01 |
2020-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3-targeting therapeutic agent which is administered to patient for whom the gpc3-targeting therapeutic agent is effective
|
TW202108592A
(zh)
|
2015-07-02 |
2021-03-01 |
瑞士商赫孚孟拉羅股份公司 |
苯并氧氮呯噁唑啶酮化合物及其用途
|
CN107995911B
(zh)
|
2015-07-02 |
2020-08-04 |
豪夫迈·罗氏有限公司 |
苯并氧氮杂*噁唑烷酮化合物及其使用方法
|
RS62260B1
(sr)
|
2015-08-21 |
2021-09-30 |
Morphosys Ag |
Kombinacije i njihova upotreba
|
CA2998469A1
(en)
|
2015-09-14 |
2017-03-23 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
|
US11352426B2
(en)
|
2015-09-21 |
2022-06-07 |
Aptevo Research And Development Llc |
CD3 binding polypeptides
|
WO2017103825A1
(en)
|
2015-12-18 |
2017-06-22 |
Lupin Limited |
Quinolizinone derivatives as pi3k inhibitors
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
SG11201811237WA
(en)
|
2016-06-24 |
2019-01-30 |
Infinity Pharmaceuticals Inc |
Combination therapies
|
EP3272348A1
(en)
|
2016-07-21 |
2018-01-24 |
LEK Pharmaceuticals d.d. |
Pharmaceutical composition comprising idelalisib
|
WO2018057808A1
(en)
|
2016-09-23 |
2018-03-29 |
Gilead Sciences, Inc. |
Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
CN108239074B
(zh)
*
|
2016-12-26 |
2021-07-06 |
中国医学科学院药物研究所 |
喹唑啉类化合物及其制备方法、用途和药物组合物
|
CN110382490A
(zh)
*
|
2016-12-26 |
2019-10-25 |
中国医学科学院药物研究所 |
喹唑啉类化合物及其制备方法、用途和药物组合物
|
US11028068B2
(en)
|
2017-07-25 |
2021-06-08 |
Crinetics Pharmaceuticals, Inc. |
Somatostatin modulators and uses thereof
|
US11459306B2
(en)
*
|
2017-07-31 |
2022-10-04 |
The Trustees Of Columbia University In The City Of New York |
Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia
|
CN111212643A
(zh)
|
2017-08-14 |
2020-05-29 |
梅制药公司 |
联合疗法
|
AR113922A1
(es)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
|
CN112105608B
(zh)
|
2018-01-30 |
2023-07-14 |
因赛特公司 |
制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
|
WO2019178596A1
(en)
|
2018-03-16 |
2019-09-19 |
Johnson Matthey Public Limited Company |
Pyridine or n,n-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation
|
AU2019245420A1
(en)
|
2018-03-30 |
2020-11-12 |
Incyte Corporation |
Treatment of hidradenitis suppurativa using JAK inhibitors
|
WO2020038394A1
(zh)
*
|
2018-08-21 |
2020-02-27 |
南京明德新药研发有限公司 |
吡唑并嘧啶衍生物及其作为pi3k抑制剂的应用
|
US11999716B2
(en)
|
2018-10-24 |
2024-06-04 |
Vanderbilt University |
WDR5 inhibitors and modulators
|
EP3877511A1
(en)
|
2018-11-05 |
2021-09-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
CN111269231B
(zh)
*
|
2018-12-04 |
2023-06-09 |
安徽中科拓苒药物科学研究有限公司 |
一种选择性PI3Kδ抑制剂及其用途
|
WO2020201073A1
(en)
*
|
2019-03-29 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
|
WO2020247679A1
(en)
*
|
2019-06-04 |
2020-12-10 |
Vanderbilt University |
Wdr5 inhibitors and modulators
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
CN112830927A
(zh)
*
|
2021-03-04 |
2021-05-25 |
山西科灜科技有限公司 |
一种嘌呤喹唑啉酮衍生物及其制备方法
|